Following publication of the positive outcomes of the BANDIT trial in NEJM in December 2023, ATIC has received many enquiries about the use of baricitinib for the treatment of type 1 diabetes. The BANDIT team, with support from ATIC’s Community Engagement Panel and Steering Committee, prepared a position statement to provide guidance and inform decision making for health care professionals considering prescribing off-label baricitinib to treat type 1 diabetes. The position statement, along with a community information sheet are available for review and download here:

Baricitinib position statement

Community Statement

A group of ATIC clinician-researchers with support from JDRFA have published the Australian guidelines for care pathways for people with early-stage type 1 diabetes. The Australian guidelines were developed concurrently with the international ‘consensus guidance for monitoring individuals with islet autoantibody‑positive pre‑stage 3 type 1 diabetes’. The new care pathways, along with the international guidelines are available for review and download here:

Care pathways for people with early stage type 1 diabetes in Australia

International consensus guidelines

ATIC offers a range of services for both investigator-initiated and commercial clinical trials. Services are tailored to each study’s specific study requirements and developed in close collaboration between the sponsor and ATIC’s scientifically engaged management team.

Download ATIC Standard Services

The ATIC Community Engagement Panel has lead the development of a video resource designed to educate health professionals and the community about the stages of type 1 diabetes and the opportunities that new disease-modifying, immunotherapy treatments present. This resource explores how immunotherapy treatments can preserve insulin-producing cells and transform the future of type 1 diabetes care.

The Panel co-wrote the script and provided voiceovers, ensuring the video represents the diversity of the type 1 diabetes community in Australia.

This resource bridges the gap between complex medical research and community understanding, offering hope to individuals diagnosed with type 1 diabetes and their families. By combining clinical expertise with lived experience, the video serves as both an educational tool and a source of inspiration for the type 1 diabetes community.

Acknowledgement
This video resource was developed by the Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) with leadership and input from the ATIC Community Engagement Panel, who guided its development to ensure it reflects the experiences and voices of our local type 1 diabetes community.

We gratefully acknowledge the community members whose voices bring this story to life and represent the diversity of the Australian type 1 diabetes community: Flynn, Annie, Emma, Kelly and Michaela.

ATIC sincerely thanks T1DUK for generously sharing their original animation, which made it possible to create this new Australian resource.